New hope for hepatitis b: Real-World trial of pradefovir underway

NCT ID NCT07555340

Ongoing Disease control Sponsor: Juan Li Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a drug called pradefovir mesylate in 400 adults with chronic hepatitis B. The goal is to see how well it lowers the virus and how safe it is in everyday medical practice, not just in a strict research setting. Participants are being followed for up to 65 weeks to check if the virus becomes undetectable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pradefovir mesylate tablets
What this could lead to: If successful, this could confirm pradefovir as a safe and effective antiviral option for controlling chronic hepatitis B, potentially reducing liver damage and transmission risk.
What could go wrong: This is an observational real-world study, not a randomized controlled trial, so results may be less definitive. The drug may not work for all patients or could have side effects not fully captured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Locations

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.